Cystatin B Downregulation Restricts HIV Replication in Placental Macrophages

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The mechanisms behind restricted HIV replication in placental macrophages (PM) are not fully understood, despite lower viral replication levels compared to peripheral blood monocyte-derived macrophages (MDM), and current host factors like leukemia inhibitory factor (LIF) and human chorionic gonadotropin beta-subunit (hCG) only provide partial inhibition.

Innovation Solution

A proteomics approach using SELDI-TOF MS, 1D-gel electrophoresis, and LC-MS/MS identifies cystatin B (CSTB) as a protein differentially expressed between uninfected and HIV-infected PM and MDM, with siRNA studies demonstrating reduced CSTB levels contributing to innate resistance and decreased HIV replication.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If conventional host factors like LIF and hCG are used to inhibit HIV replication, then partial viral inhibition is achieved, but complete restriction of HIV replication in PM is not attained

Engineering Contradiction:

ImproveHIV replicationVSAvoidinhibition effectiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The invention identifies and targets specific molecular parameters (CSTB protein expression levels) that differ between PM and MDM. By changing the parameter of cystatin B expression to low levels, the system achieves complete HIV replication restriction, overcoming the partial inhibition provided by conventional factors like LIF and hCG.

Inventive Principle:

Principle #35Parameter changes

2Loss of information

If proteomics approaches like SELDI-TOF MS and LC-MS/MS are used to identify host factors, then novel proteins like CSTB are discovered, but the complexity of the identification process increases

Engineering Contradiction:

Improveidentification of host factorsVSAvoidproteomics methodology

Core Design Contradiction:

Loss of informationVSDevice complexity

Solution Approach 1:

The proteomics approach is segmented into distinct sequential steps: SELDI-TOF MS for initial protein profiling and identification of differential peaks, followed by LC-MS/MS for definitive protein identification of selected peaks. This segmentation allows systematic analysis of complex proteomes while managing technical complexity through staged identification.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention uses proteomics technology as an intermediary tool to bridge the gap between observing HIV restriction phenomena and identifying the molecular mechanisms. SELDI-TOF MS and LC-MS/MS serve as intermediary techniques that translate complex biological samples into identifiable protein profiles, revealing CSTB as the key host factor.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If CSTB expression is reduced in PM, then innate resistance to HIV infection increases, but the mechanism by which CSTB restriction occurs remains unknown

Engineering Contradiction:

Improveinnate resistance to HIVVSAvoidintracellular mechanisms

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The invention converts the unknown mechanism into a benefit by using siRNA technology to deliberately reduce CSTB expression and observe the effect. By knocking down CSTB and observing decreased HIV replication, the study transforms the lack of mechanistic knowledge into an experimental approach that reveals CSTB's protective role and suggests intracellular pathways involving cysteine protease inhibition.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Reduced CSTB expression in PM is associated with decreased HIV replication and innate resistance, potentially protecting against maternal-fetal viral transmission, suggesting CSTB as a key factor in HIV restriction in PM.

Implementation Method 1

surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS)

Methodology Applied

Scientific EffectSurface-enhanced laser desorption/ionization: Laser Ablation

Implementation Method 2

1D-gel electrophoresis

Methodology Applied

Scientific EffectElectrophoresis: Electrophoresis

Implementation Method 3

liquid chromatography tandem MS (LC-MS/MS)

Methodology Applied

Scientific EffectLiquid chromatography: Chromatography

Data Source

PatentUS8143231B1Method of reducing HIV-replication in human body tissue

Publication Date: 2012.03.27 PUERTO RICO UNIV OF

AI summary

Mononuclear phagocytes are reservoirs, vehicles of dissemination, and targets for persistent HIV infection. However, not all MP population equally support viral growth. Such differential replication is typified by the greater ability of placental macrophages (PM), as compared to blood borne monocyte-derived macrophages (MDM), to restrict viral replication. A SELDI-TOF protein peak with an m/z of 11,100 identified as cystatin B (CSTB), was significantly lower in uninfected and HIV-infected PM than in MDM. HIV replication can be reduced by down regulating the expression of Cystatin B.